stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Return on assets
Mirum Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was −99.8%, down 96.7 percentage points from fiscal 2025 (−3.09%). Over the past ten years it has ranged from −66.8% (fiscal 2018) to −3.09% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −3.09% | 10.26 |
| FY2024 | −13.4% | 19.35 |
| FY2023 | −32.7% | 9.20 |
| FY2022 | −41.9% | (10.53) |
| FY2021 | −31.4% | 21.92 |
| FY2020 | −53.3% | (0.39) |
| FY2019 | −52.9% | 13.86 |
| FY2018 | −66.8% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| MIRM Mirum Pharmaceuticals, Inc. | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement